Adma Biologics (ADMA) Free Cash Flow Growth (3y) (2016 - 2025)
Adma Biologics (ADMA) Free Cash Flow Growth (3y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Adma Biologics | 2.04 Bn | 1.95 Bn | 88.82 Mn | 72.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 72.19% |
| Sep 30, 2025 | 59.89% |
| Jun 30, 2025 | 46.06% |
| Mar 31, 2025 | 5.47% |
| Dec 31, 2024 | 48.55% |
| Sep 30, 2024 | 51.53% |
| Jun 30, 2024 | 47.15% |
| Mar 31, 2024 | 49.67% |
| Dec 31, 2023 | 34.95% |
| Sep 30, 2023 | 34.26% |
| Jun 30, 2023 | 35.18% |
| Mar 31, 2023 | 14.56% |
| Dec 31, 2022 | 19.39% |
| Sep 30, 2022 | 13.33% |
| Jun 30, 2022 | 3.67% |
| Mar 31, 2022 | -26.08% |
| Dec 31, 2021 | -23.72% |
| Sep 30, 2021 | -8.25% |
| Jun 30, 2021 | -33.60% |
| Mar 31, 2021 | -28.22% |